Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Allory

Showing results (21-30 of 229) with videos related to

Pageof 23
Sort By:
Contemporary Clinical Trials Communications|February 22, 2020
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trialChristian Pfister, Valentin Harter, Yves Allory, et al.
Virchows Archiv : an International Journal of Pathology|April 10, 2003
Papillary renal cell carcinoma. Prognostic value of morphological subtypes in a clinicopathologic study of 43 casesYves Allory, Delphine Ouazana, Eric Boucher, et al.
European Urology Oncology|January 23, 2026
Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key FactorChristian Pfister, Valentin Harter, Jacqueline Fontugne, et al.
Genome Biology|July 24, 2010
Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesisEric Letouzé, Yves Allory, Marc A Bollet, et al.
The Journal of Urology|December 28, 2023
Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER TrialYves Allory, Stephane Culine, Clémentine Krucker, et al.
BMC Cancer|November 5, 2016
A prospective multicenter study on bladder cancer: the COBLAnCE cohortSimone Benhamou, Julia Bonastre, Karine Groussard, et al.
Urology|December 5, 2006
Adenocarcinoma of ileal neobladder 20 years after cystectomyJean Paul Berberian, Lieven Goeman, Yves Allory, et al.
The American Journal of Surgical Pathology|May 18, 2005
Sarcomatoid variant of anaplastic large cell lymphoma mimics ALK-1-positive inflammatory myofibroblastic tumor in bladderYves Allory, Zahira Merabet, Christiane Copie-Bergman, et al.
World Journal of Urology|March 28, 2014
DNA comparison between operative and biopsy specimens to investigate stage pT0 after radical prostatectomyThomas Bessede, Emmanuelle Girodon, Yves Allory, et al.
The American Journal of Pathology|January 28, 2003
Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinomaEl Chérif Ibrahim, Yves Allory, Frédéric Commo, et al.
Pageof 23

Showing results (21-30 of 229) with videos related to

Sort By:
Pageof 23
Contemporary Clinical Trials Communications|February 22, 2020
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trialChristian Pfister, Valentin Harter, Yves Allory, et al.
Virchows Archiv : an International Journal of Pathology|April 10, 2003
Papillary renal cell carcinoma. Prognostic value of morphological subtypes in a clinicopathologic study of 43 casesYves Allory, Delphine Ouazana, Eric Boucher, et al.
European Urology Oncology|January 23, 2026
Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key FactorChristian Pfister, Valentin Harter, Jacqueline Fontugne, et al.
Genome Biology|July 24, 2010
Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesisEric Letouzé, Yves Allory, Marc A Bollet, et al.
The Journal of Urology|December 28, 2023
Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER TrialYves Allory, Stephane Culine, Clémentine Krucker, et al.
BMC Cancer|November 5, 2016
A prospective multicenter study on bladder cancer: the COBLAnCE cohortSimone Benhamou, Julia Bonastre, Karine Groussard, et al.
Urology|December 5, 2006
Adenocarcinoma of ileal neobladder 20 years after cystectomyJean Paul Berberian, Lieven Goeman, Yves Allory, et al.
The American Journal of Surgical Pathology|May 18, 2005
Sarcomatoid variant of anaplastic large cell lymphoma mimics ALK-1-positive inflammatory myofibroblastic tumor in bladderYves Allory, Zahira Merabet, Christiane Copie-Bergman, et al.
World Journal of Urology|March 28, 2014
DNA comparison between operative and biopsy specimens to investigate stage pT0 after radical prostatectomyThomas Bessede, Emmanuelle Girodon, Yves Allory, et al.
The American Journal of Pathology|January 28, 2003
Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinomaEl Chérif Ibrahim, Yves Allory, Frédéric Commo, et al.
Pageof 23